Overview

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-12-11

Target enrollment:

Participant gender:

Summary

It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for durable responses.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

National Comprehensive Cancer Network

Treatments:

Futibatinib
Pembrolizumab